DSM-Firmenich AG

ENXTAM:DSM Stock Report

Market Cap: €763.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

DSM-Firmenich Future Growth

Future criteria checks 4/6

DSM-Firmenich is forecasted to grow earnings and revenue by 20.5% and 11.1% per annum respectively. EPS is expected to grow by 18.3%. Return on equity is forecast to be 6.1% in 3 years.

Key information

20.5%

Earnings growth rate

18.34%

EPS growth rate

Chemicals earnings growth20.1%
Revenue growth rate11.1%
Future return on equity6.07%
Analyst coverage

Good

Last updated31 May 2023

Recent future growth updates

Recent updates

Analysis Article • May 04

Analyst Forecasts For Koninklijke DSM N.V. (AMS:DSM) Are Surging Higher

Koninklijke DSM N.V. ( AMS:DSM ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article • Mar 27

Koninklijke DSM (AMS:DSM) Is Reinvesting At Lower Rates Of Return

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...
Analysis Article • Mar 09

Is Koninklijke DSM (AMS:DSM) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Dec 06

Here's Why We Think Koninklijke DSM (AMS:DSM) Is Well Worth Watching

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article • Nov 18

Is Koninklijke DSM (AMS:DSM) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Oct 31

Estimating The Fair Value Of Koninklijke DSM N.V. (AMS:DSM)

In this article we are going to estimate the intrinsic value of Koninklijke DSM N.V. ( AMS:DSM ) by taking the expected...
Analysis Article • Sep 19

Why Koninklijke DSM N.V. (AMS:DSM) Could Be Worth Watching

Let's talk about the popular Koninklijke DSM N.V. ( AMS:DSM ). The company's shares received a lot of attention from a...
Analysis Article • Aug 23

Is Now The Time To Put Koninklijke DSM (AMS:DSM) On Your Watchlist?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Analysis Article • Aug 08

Is Koninklijke DSM (AMS:DSM) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jul 23

Calculating The Intrinsic Value Of Koninklijke DSM N.V. (AMS:DSM)

How far off is Koninklijke DSM N.V. ( AMS:DSM ) from its intrinsic value? Using the most recent financial data, we'll...
Analysis Article • Apr 30

Koninklijke DSM (AMS:DSM) Is Increasing Its Dividend To €1.70

Koninklijke DSM N.V.'s ( AMS:DSM ) dividend will be increasing to €1.70 on 1st of June. Although the dividend is now...
Analysis Article • Apr 16

Koninklijke DSM (AMS:DSM) Is Increasing Its Dividend To €1.70

Koninklijke DSM N.V.'s ( AMS:DSM ) dividend will be increasing to €1.70 on 1st of June. Although the dividend is now...
Analysis Article • Apr 02

Koninklijke DSM's (AMS:DSM) Upcoming Dividend Will Be Larger Than Last Year's

The board of Koninklijke DSM N.V. ( AMS:DSM ) has announced that it will be increasing its dividend on the 1st of June...
Analysis Article • Mar 19

Koninklijke DSM's (AMS:DSM) Dividend Will Be Increased To €1.70

The board of Koninklijke DSM N.V. ( AMS:DSM ) has announced that it will be increasing its dividend on the 1st of June...
Analysis Article • Feb 19

Koninklijke DSM (AMS:DSM) Seems To Use Debt Rather Sparingly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Nov 23

Are Koninklijke DSM N.V. (AMS:DSM) Investors Paying Above The Intrinsic Value?

How far off is Koninklijke DSM N.V. ( AMS:DSM ) from its intrinsic value? Using the most recent financial data, we'll...
Analysis Article • Oct 01

We Think Koninklijke DSM (AMS:DSM) Can Stay On Top Of Its Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Aug 24

Does This Valuation Of Koninklijke DSM N.V. (AMS:DSM) Imply Investors Are Overpaying?

Does the August share price for Koninklijke DSM N.V. ( AMS:DSM ) reflect what it's really worth? Today, we will...
Analysis Article • Jun 29

Koninklijke DSM (AMS:DSM) Has A Pretty Healthy Balance Sheet

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • May 24

Koninklijke DSM N.V.'s (AMS:DSM) Intrinsic Value Is Potentially 17% Below Its Share Price

Does the May share price for Koninklijke DSM N.V. ( AMS:DSM ) reflect what it's really worth? Today, we will estimate...
Analysis Article • Mar 29

Is Koninklijke DSM (AMS:DSM) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Mar 15

Should Koninklijke DSM N.V. (AMS:DSM) Be Part Of Your Dividend Portfolio?

Is Koninklijke DSM N.V. ( AMS:DSM ) a good dividend stock? How can we tell? Dividend paying companies with growing...
Analysis Article • Mar 01

Are Koninklijke DSM N.V.'s (AMS:DSM) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Koninklijke DSM (AMS:DSM) has had a rough month with its share price down 5.2%. However, the company's fundamentals...
Analysis Article • Feb 16

Koninklijke DSM (AMS:DSM) Has Gifted Shareholders With A Fantastic 276% Total Return On Their Investment

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
Analysis Article • Feb 04

Need To Know: Koninklijke DSM N.V. (AMS:DSM) Insiders Have Been Selling Shares

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

Earnings and Revenue Growth Forecasts

ENXTAM:DSM - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202514,6651,0147491,9878
12/31/202413,9346858471,9669
12/31/202312,0245443441,3119
12/31/20228,390454314965N/A
9/30/20229,5828374121,056N/A
6/30/20229,8021,0825101,147N/A
3/31/20229,5031,0816801,287N/A
12/31/20217,2698208501,427N/A
9/30/20217,9556608841,507N/A
6/30/20217,5584939061,489N/A
3/31/20217,5724239061,497N/A
12/31/20208,1064488681,494N/A
9/30/20207,9605108091,434N/A
6/30/20208,0345578101,462N/A
3/31/20209,0117228261,471N/A
12/31/20197,9986757441,385N/A
9/30/20198,2728207661,399N/A
6/30/20198,5027947471,395N/A
3/31/20199,1249346121,282N/A
12/31/20189,2671,0696981,391N/A
9/30/20189,2359846571,310N/A
6/30/20189,1062,0825501,170N/A
3/31/20188,9081,9425121,110N/A
12/31/20178,6321,761441996N/A
9/30/20178,4711,676431993N/A
6/30/20178,3337384701,028N/A
3/31/20178,1667115541,077N/A
12/31/20167,9206455231,018N/A
9/30/20167,831588N/A958N/A
6/30/20167,778274N/A914N/A
3/31/20167,749214N/A811N/A
12/31/20157,722174N/A696N/A
9/30/20157,60766N/A800N/A
6/30/20157,456114N/A820N/A
3/31/20157,245115N/A867N/A
12/31/20147,051123N/A808N/A
9/30/20147,415112N/A866N/A
6/30/20147,834138N/A885N/A
3/31/20148,362182N/A1,010N/A
12/31/20138,858252N/A998N/A
9/30/20138,409363N/A705N/A
6/30/20138,500335N/A638N/A
3/31/20138,486257N/A584N/A
12/31/20128,588280N/A730N/A
9/30/20129,089453N/A950N/A
6/30/20129,107543N/A1,020N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DSM's forecast earnings growth (20.5% per year) is above the savings rate (0.4%).

Earnings vs Market: DSM's earnings (20.5% per year) are forecast to grow faster than the Dutch market (16.1% per year).

High Growth Earnings: DSM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: DSM's revenue (11.1% per year) is forecast to grow faster than the Dutch market (3.9% per year).

High Growth Revenue: DSM's revenue (11.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DSM's Return on Equity is forecast to be low in 3 years time (6.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/05/31 08:06
End of Day Share Price 2023/05/30 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DSM-Firmenich AG is covered by 42 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jennifer BarkerBarclays
Alexander SloaneBarclays
Sebastian BrayBerenberg